Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01564784 · ClinicalTrials.gov registry record · Phase 3
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT01564784 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 326 participants.
The verdict
NCT01564784, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
Interventions
- DRUG inotuzumab ozogamicin
- DRUG FLAG (fludarabine, cytarabine and G-CSF)
- DRUG HIDAC (high dose cytarabine)
- DRUG cytarabine and mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2012-08-02 |
| Est. Completion | 2017-01-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01564784
The ClinicalTrials.gov registry entry for NCT01564784 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which inotuzumab ozogamicin is the first listed.
NCT01564784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01564784 about?
NCT01564784 is a clinical study titled "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia". This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
What is the current status of trial NCT01564784?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2012-08-02. Estimated completion is 2017-01-04.
What interventions are being tested in trial NCT01564784?
The interventions under investigation include: inotuzumab ozogamicin (DRUG), FLAG (fludarabine, cytarabine and G-CSF) (DRUG), HIDAC (high dose cytarabine) (DRUG), cytarabine and mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT01564784?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.